Cellectis is pioneering robust first-in-class allogeneic CAR T-cell programs that address multiple unmet cancer needs. These programs were designed with simplicity, availability and cost-effectiveness for patients.
UCARTs are “off-the-shelf” allogeneic product candidates, whose production can be industrialized and thereby standardized with consistent pharmaceutical release criteria, over time and from batch to batch.
Our comprehensive, scalable, efficient and cost-effective manufacturing process generates highly potent CAR T therapies.
Our product candidates, based on gene-edited allogeneic T-cells that express Chimeric Antigen Receptors, or CARs, seek to harness the power of the immune system to target and eradicate cancer cells.